Oncogenic Addiction to ERBB2 Signaling Predicts Response to Trastuzumab in Urothelial Cancer.
Karass M, Bareja R, Shelkey E, Vlachostergios PJ, Robinson BD, Khani F, Mosquera JM, Scherr DS, Sboner A, Tagawa ST, Molina AM, Elemento O, Nanus DM, Faltas BM.
Karass M, et al. Among authors: shelkey e.
J Natl Compr Canc Netw. 2019 Mar 1;17(3):194-200. doi: 10.6004/jnccn.2018.7264.
J Natl Compr Canc Netw. 2019.
PMID: 30865916